In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biohaven Pharmaceutical Holding Co. Ltd.

www.biohavenpharma.com

Latest From Biohaven Pharmaceutical Holding Co. Ltd.

Biopharma Quarterly Dealmaking Statistics, Q2 2019

Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.

Market Intelligence Deals

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

GW Pharma’s Cannabidiol For Seizures One Step Closer To European Approval

The CHMP has issued a positive opinion for Epidyolex for two rare conditions. The cannabidiol product was approved in the US in 2018.

Approvals Neurology

Kleo Brings Small-Molecule Approach To IO With Three Technological Applications

Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.

ImmunoOncology Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Biohaven Pharmaceuticals
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biohaven Pharmaceutical Holding Co. Ltd.
  • Senior Management
  • Vlad Coric, MD, CEO
    Jim Engelhart, CFO
    Robert Berman, MD, CMO
    John Tilton, Chief Commercial Officer
    Charlie Conway, PhD, CSO
    Elyse Stock, MD, Chief, Portfolio Strategy & Dev.
    Donnie McGrath, MD, Chief, Corp. Strategy & Bus. Dev.
    Kim Gentile, VP, Operations
  • Contact Info
  • Biohaven Pharmaceutical Holding Co. Ltd.
    Phone: (203) 404-0410
    234 Church St.
    New Haven, CT 06510
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register